News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

November 7, 2018

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

August 20, 2018

Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions

 

SOUTHBOROUGH, MA –  August 20, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 

Read More

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

August 16, 2018

 The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

 

SOUTHBOROUGH, MA –  August 16, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.

Read More